Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Physician-diagnosed asthma for at least 12 months prior to screening~* Documented history of positive skin test or in vitro reactivity to a perennial aeroallergen~* Able to comply with asthma control medication adherence, digital monitoring data collection, and eDiary requirements during screening period~* Able to safely complete incremental exercise tolerance at screening~* Pre-bronchodilator FEV1 of 40%-80% of predicted at screening~* Documented history of variable airflow obstruction or hyper-responsiveness within 12 months of study entry~* On inhaled corticosteroids (ICS) therapy at a total daily dose greater than or equal to (≥)500 micrograms (ug) of fluticasone propionate or equivalent and at least one second controller (LABA, LAMA, LTRA) for ≥3 months prior to screening~* Uncontrolled asthma during the screening period, defined as an ACQ-5 ≥0.75 score~* Sleep disturbance due to asthma (e.g. cough, wheezing etc.) in the opinion of the investigator~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to use adequate contraception during the treatment period and for 60 days after the final dose of study drug.~Exclusion Criteria:~* Known history of anaphylaxis/hypersensitivity to omalizumab~* Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening~* Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) for 6 months prior to screening~* Maintenance oral corticosteroid therapy, defined as daily or alternate-day oral corticosteroid within 3 months prior to screening or during the screening period~* Treatment with systemic (oral, IV, or IM) corticosteroids within 4 weeks prior to screening or during the screening period~* Isolated diagnosis of exercise induced asthma without chronic symptoms~* History of interstitial lung disease, COPD, or other clinically significant lung disease other than asthma~* Current malignancy or history of malignancy within 5 years prior to screening~* Unable to complete cardiopulmonary exercise testing and/or perform physical activity due to underlying cardiac, neurologic or orthopedic conditions~* Ongoing physician-treated sleep disorder that is unrelated to asthma within 6 months prior to screening~* Current smoker or past smoker with \>10 pack years~* Known HIV infection at screening~* Known acute or chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening~* Infection that resulted in hospital admission, required treatment with intravenous or intramuscular antibiotics within 4 weeks prior to screening, or any active infection that required treatment with oral antibiotics within 2 weeks prior to screening~* Active tuberculosis requiring treatment within 12 months prior to screening~* History of alcohol, drug, or chemical abuse within 6 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues